Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto

Abstract

The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of such a protein and a pharmaceutical composition containing it are highly useful for proliferative diseases, particularly as anticancer agents. By providing the novel target protein, the mechanism behind the anticancer effect that has conventionally been unexplainable can be elucidated.

1 - 20 . (canceled) 
     
     
         21 . A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises:
 (1) bringing KSRP or a functional fragment thereof into contact with a compound, wherein the compound is not an antibody,   (2) determining whether or not the compound specifically binds to KSRP or a functional fragment thereof, and   (3) selecting a compound that specifically binds to KSRP or a functional fragment thereof.   
     
     
         22 . A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises:
 (1) bringing a protein having the amino acid sequence of SEQ ID NO:2 or a functional fragment thereof into contact with a compound, wherein the compound is not an antibody,   (2) determining whether or not the compound specifically binds to the protein or a functional fragment thereof, and   (3) selecting a compound that specifically binds to the protein or a functional fragment thereof.   
     
     
         23 . A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises:
 (1) bringing a protein having the amino acid sequence of SEQ ID NO:2, wherein one or more amino acids are deleted, substituted or added, and which:   (i) binds to a compound of formula 1, and   (ii) does not bind to a compound of formula 2   
       
         
           
           
               
               
           
         
       
       or a functional fragment thereof into contact with a compound, wherein the compound is not an antibody
 (2) determining whether or not the compound specifically binds to the protein or a functional fragment thereof, and 
 (3) selecting a compound that specifically binds to the protein or a functional fragment thereof. 
 
     
     
         24 . A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises:
 (1) bringing a protein having the amino acid sequence of SEQ ID NO:3 or a functional fragment thereof into contact with a compound, wherein the compound is not an antibody,   (2) determining whether or not the compound specifically binds to the protein or a functional fragment thereof, and   (3) selecting a compound that specifically binds to the protein or a functional fragment thereof.   
     
     
         25 . A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which method comprises:
 (1) bringing a protein having the amino acid sequence of SEQ ID NO:3, wherein one or more amino acids are deleted, substituted or added, and which:   (i) binds to a compound of formula 1, and   (ii) does not bind to a compound of formula 2   
       
         
           
           
               
               
           
         
       
       or a functional fragment thereof into contact with a compound, wherein the compound is not an antibody,
 (2) determining whether or not the compound specifically binds to the protein or a functional fragment thereof, and 
 (3) selecting a compound that specifically binds to the protein or a functional fragment thereof. 
 
     
     
         26 - 33 . (canceled)